ORCL · Investment summary · as of 3 August 2026
Priced close to what the business has demonstrated
Business type: Compounder · mature and structurally stable
At $141.84, ORCL requires a 13% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 17%.
Axes AGREE (+4.04pp growth, +4.26pp margin slack). The disagreement with the market is growth durability (RPO conversion), not margin structure.
The value rests on an exit multiple of 28.4x, a terminal operating margin of 30% and a 9.5% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Named cause: non-performance or renegotiation by one of the three counterparties holding ~half the $638bn RPO book (>=49.8% traces to four Q1-FY2026 contracts).
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Axes AGREE (+4.04pp growth, +4.26pp margin slack). The disagreement with the market is growth durability (RPO conversion), not margin structure. |
| What do we forecast? | Revenue growth of 17% demonstrated; a terminal operating margin of 30%; an exit multiple of 28.4x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +4.0 percentage points. |
| What is it worth? | Twelve-month target $164.00, +16% from the struck price. Scenario-weighted expected return net of costs +15.4%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 10 September 2026 | Next results (date estimated, not issuer-confirmed) | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.
Named cause: non-performance or renegotiation by one of the three counterparties holding ~half the $638bn RPO book (>=49.8% traces to four Q1-FY2026 contracts). STATED LOSS: -26.0% (clean EPS $4.93 flat x own 5y P/E p10 21.30x = $105). Probability 25% (judgement, Brier-logged). At the 5y-min multiple (loss -41.2%) the threshold tightens to 24.3%, marginally below the stated 25% - the budget verdict straddles the multiple assumption, disclosed. Not going-concern: interest coverage ~4.5x vs 3.0x covenant, $31.9bn liquid, $75bn customer prepaid/supplied hardware; management committed to IG rating.
Falsifiable and fundamental — not one of them is a price condition.
Trim/exit when forward E[R] <= 0 net of costs: at/above ~$164 without estimate upgrades the base 12m E[R] is exhausted. On approach to the $164.00 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Named cause: non-performance or renegotiation by one of the three counterparties holding ~half the $638bn RPO book (>=49.8% traces to four Q1-FY2026 contracts). |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Met | Is there a dated event that resolves the disagreement? |
| Consensus | Met | Is the house-versus-Street disagreement identified and quantified? |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +4.0 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: named cause: non-performance or renegotiation by one of the three counterparties holding ~half the $638bn RPO book (>=49.8% traces to four Q1-FY2026 contracts). The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $120.26, which forces an immediate review.